drugset

drugset / Trial / NCT00748982

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

NCT00748982 ↗

Phase 2 Completed 16 enrolled AstraZeneca

RandomizedParallel-groupSingle-blindTreatment

Summary

To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction

Timeline

Start: 2008-08
Primary completion: 2009-07
Completion: 2009-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AZD1305	Small molecule	—	Intravenous

Indications